FDA slaps Hong Kong OTC drugmaker Nan San Pharma with warning letter

FDA Warning
FDA slaps Hong Kong OTC drugmaker Nan San Pharma with warning letter.

The FDA issued a warning letter to Hong Kong-based OTC drugmaker Nan San Pharmaceutical for failing to conduct appropriate laboratory testing and marketing misbranded products in the U.S.

An inspection of the company’s facility in Kwun Tong Kowloon, Hong Kong last September resulted in Nan San being placed on the regulatory agency’s import alert list in January.

In its warning letter, the FDA says inspectors found the company failed to perform microbial limit tests on batches of one of its products from 2013 to 2016. It found Nan San performed microbial limit testing on one batch in 2013 and used those results to release “subsequently-manufactured batches” to the U.S.

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

Additionally, the agency cited the company for setting expiration dates for some of its products without properly determining the stability characteristics of those products.

Musflex and Easy-Flex, two of Nan San’s OTC products, were found to be misbranded because their labels didn’t list active or inactive ingredients.

The FDA recently hit another Chinese OTC drugmaker, Zhejiang Ludao Technology, with a warning letter for data integrity and product testing issues.

Suggested Articles

Sanofi, a hydroxychloroquine maker, is producing as much as it can amid the pandemic, but some workers are having to exit the line manufacturing line.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.

Nearly four decades after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.